XORTX Therapeutics Inc.

XORTX Therapeutics, Inc.'s next confirmed earnings release is scheduled for November 12, 2026.

As of June 30, 2026, XORTX Therapeutics, Inc. has 1.73M shares outstanding.

As of June 30, 2026, XORTX Therapeutics, Inc. maintains a current ratio of 3.59, meaning it holds 3.6x the short-term assets needed to cover near-term liabilities.

Over the twelve months ended June 30, 2026, XORTX Therapeutics, Inc. posted a negative return on equity (ROE) of -99.24, meaning shareholder capital produced losses rather than profits. Return on assets (ROA) is negative at -83.78, reflecting losses generated across the asset base. The company generates approximately - - in revenue per employee across its workforce of 3.00, a quick read on workforce productivity versus industry peers.

Over the twelve months ended June 30, 2026, XORTX Therapeutics, Inc. generated - - in revenue and converted that into -3.27M in net income, yielding earnings per share of -2.47. EBITDA reached -3.34M, while operating income came in at -3.43M.

These figures are as of June 30, 2026. Total book value stands at 4.82M, with working capital of 1.54M providing operational flexibility.

XORTX Therapeutics, Inc. produced -4.46M in operating cash flow over the twelve months ended June 30, 2026. After subtracting -155,272.09 in capital expenditures, free cash flow totaled -4.62M - equivalent to -3.49 per share.

XORTX Therapeutics, Inc.'s most recent stock split took place on April 6, 2026 with a 5:1 split ratio.